Dr. Robert Hariri will explore the transformative potential of cellular medicine in extending human longevity and optimizing performance. His session will highlight how next-generation cellular therapies are redefining healthcare, moving beyond disease treatment to proactive restoration and maintenance of the body’s regenerative systems. Drawing on his pioneering work in stem cell science and regenerative technologies, Dr. Hariri will discuss how these innovations can help preserve vitality, resilience, and cognitive performance throughout the aging process.

He will also share insights into the emerging convergence of cellular biology, biotechnology, and precision medicine, revealing how these fields together are shaping a new era of healthspan enhancement.

Dr. Robert J. Hariri, is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace. He is the chairperson, founder, and chief executive officer of Celularity, Inc., one of the world’s leading human cellular therapeutics companies. 

Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. He also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Dr. Hariri has served on numerous public boards including Cryoport (NASDAQ:CYRX) and pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF).

Dr. Hariri and his team of scientists were the first to obtain FDA approval to use its cryopreserved allogeneic, off-the-shelf Natural Killer (NK) cell therapy to treat COVID-19 infected adults. He holds over 170 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts.